Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_1
3
75%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
3(75.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (25.0%)
Phase 13 (75.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_1

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04648475
unknownphase_1

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04649983
unknownphase_1

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

NCT05651100
unknownearly_phase_1

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

NCT04303247

Clinical Trials (4)

Showing 4 of 4 trials
NCT04648475Phase 1

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Unknown
NCT04649983Phase 1

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Unknown
NCT05651100Phase 1

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Unknown
NCT04303247Early Phase 1

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4